Cinclus Pharma: Secured reimbursement in China - Redeye

Redeye leaves a comment following Cinclus’ announcement that its lead candidate, linaprazan glurate, has been included on China’s 2025 National Reimbursement Drug List (NRDL). We view this as an important milestone ahead of the drug’s first expected commercial launch in 2026 and a strong external validation of its scientific and strategic value. The reimbursement decision strengthens the global outlook for linaprazan glurate and supports Cinclus’ broader commercial strategy.

Länk till analysen i sin helhet: https://www.redeye.se/research/1143049/cinclus-pharma-secured-reimbursement-in-china?utm_source=finwire&utm_medium=RSS